GLP-1 receptor agonists, like Ozempic, are emerging as promising treatments for addiction, potentially transforming addiction medicine by targeting brain reward pathways. Recent studies show significant reductions in opioid overdose and alcohol intoxication rates among those treated with these drugs, suggesting a new frontier in addressing substance use disorders. Simultaneously, the integration of AI in healthcare is set to enhance clinical trials and reduce administrative burdens, despite challenges in data quality, cost, and regulation.